HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy

Guillaume J. Besson,1 Christina M. Lalama,2 Ronald J. Bosch,2 Rajesh T. Gandhi,3 Margaret A. Bedison,1 Evgenia Aga,2 Sharon A. Riddler,1 Deborah K. McMahon,1 Feiyu Hong,1 and John W. Mellors1

1Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania; 2Center for Biostatistics in AIDS Research, Harvard School of Public Health, and 3Massachusetts General Hospital and Ragon Institute, Harvard Medical School, Boston

Background. Human immunodeficiency virus type 1 (HIV-1) DNA dynamics during long-term antiretroviral therapy (ART) are not defined.

Methods. Blood mononuclear cells obtained during 7–12 years of effective ART were assayed for total HIV-1 DNA and 2-long terminal repeat (LTR) circles by quantitative polymerase chain reaction (qPCR). Slopes of HIV-1 DNA were estimated by participant-specific linear regressions. Plasma was assayed for residual viremia (HIV-1 RNA) by qPCR.

Results. Thirty participants were studied. HIV-1 DNA decreased significantly from years 0–1 and 1–4 of ART with median decay slopes of $-0.86$ (interquartile range, $-1.05, -0.59$) and $-0.11$ ($-0.17, -0.06$) log10(copies/10^6 CD4+ T-cells)/year, respectively ($P < .001$). Decay was not significant for years 4–7 ($-0.02 [-0.06, 0.02]; P = .09$) or after year 7 of ART ($-0.006 [-0.030, 0.015]; P = .17$). All participants had detectable HIV-1 DNA after 10 years (median 439 copies/10^6 CD4+ T-cells; range: 7–2074). Pre-ART HIV-1 DNA levels were positively associated with pre-ART HIV-1 RNA levels (Spearman = 0.71, $P < .001$) and with HIV-1 DNA at years 4, 7, and 10 on ART (Spearman $\geq 0.75$, $P < .001$). No associations were found ($P \geq .25$) between HIV-1 DNA slopes or levels and % activated CD8+ T-cells (average during years 1–4) or residual viremia ($n = 18$). 2-LTR circles were detected pre-ART in 20/29 and in 8/30 participants at last follow-up.

Conclusions. Decay of HIV-1 DNA in blood is rapid in the first year after ART initiation (86% decline), slows during years 1–4 (23% decline/year), and subsequently plateaus. HIV-1 DNA decay is not associated with the levels of CD8+ T-cell activation or persistent viremia. The determinants of stable HIV-1 DNA persistence require further elucidation.

Clinical Trials Registration. NCT00001137.

Keywords. HIV-1 persistence; antiretroviral therapy; HIV-1 DNA decay; immune activation.
MATERIALS AND METHODS

Study Participants
Study participants had been enrolled in the ACTG A5001 cohort (AIDS Clinical Trials Group longitudinal linked randomized trials—ALLRT [10]) and followed to evaluate clinical, virological, and immunological outcomes. For the current study, selection criteria included the following: ART-naive; plasma HIV-1 RNA suppressed (<50 copies/mL) from week 32 of initial therapy for 10 or more years; at least 1 pre-ART peripheral blood mononuclear cell (PBMC) sample (≥5 million cells) and plasma sample (≥1.0 mL); at least 1 PBMC sample (≥5 million cells) at year 1 and at least 1 PBMC sample (≥5 million cells) and plasma sample (≥3.0 mL) at year 10. Seven of 30 participants had, at or after week 48, either transient HIV-1 RNA blips >50 copies/mL (n = 3, 81–538 copies/mL), ART interruption ≥14 consecutive days (n = 1), or both (n = 2, blip of 62 copies/mL 72 weeks prior to ART interruption; ART interruption 72 weeks prior to blip of 64 copies/mL) or treatment failure followed by resuppression after a change of regimen (n = 1).

Samples
Cryopreserved PBMCs were obtained pre-ART, 1 year post-ART, and at years 4, 7, and 10. For a subset of 10 participants, an additional sample was obtained at 12 years post-ART. All samples from each participant were assayed in batch for total HIV-1 DNA and 2-long terminal repeat (LTR) circles. Stored plasma samples at approximately years 4, 7, 10, and 12 (if available) post-ART from a subset of participants (n = 18) were tested for persistent viremia by single-copy HIV-1 RNA assay (SCA).

Quantitative Polymerase Chain Reaction Assays for Total HIV-1 DNA and 2 LTR Circles

Extraction of Nucleic Acid
Cryopreserved PBMCs were extracted following a previously described protocol [11] with sonication during the lysis step and after resuspension of nucleic acids (Branson high-intensity cup horn, sonication cycle ID#01, 60% amplitude for 10 seconds). Following estimation of total nucleic acid by NanoDrop 1000 (Thermo Scientific), samples were diluted to a final concentration of <170 ng/µL to prevent inhibition of quantitative polymerase chain reaction (qPCR).

qPCR for Total HIV-1 DNA and 2-LTR Circles
Each sample was assayed in triplicate for total HIV-1 DNA and 2-LTR circles using published qPCR methods with normalization for cellular input [11–13]. The 95% limits of detection (LOD) for the HIV-1 DNA and 2-LTR assays were 5.75 copies/10^6 and 7.5 copies/10^6 PBMC, respectively. Results were further normalized by the percentage of all blood lymphocytes that were CD4+ T-cells by flow cytometry and expressed as copies per 10^6 CD4+ T-cells.

Single-Copy HIV-1 RNA Assay for Residual Viremia
HIV-1 RNA in plasma was measured by SCA as previously described [3, 4]. Three milliliters of plasma were assayed, resulting in an LOD of 0.6 copies/mL.

Flow Cytometry
Flow cytometric analysis was performed on fresh cells [14]. Naive T cells were defined as those that stained positive for CD45RA and CD62L. Activated T cells were defined as CD3+ lymphocytes that stained positive for CD38 and HLA-DR. CD8+ T-cell activation was measured as the percentage of

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (N = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-ART age (years)</td>
<td>Median (Q1, Q3) 37 (31, 42)</td>
</tr>
<tr>
<td>Sex</td>
<td>Male 23 (77%)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td>White non-Hispanic 16 (53%)</td>
</tr>
<tr>
<td>Pre-ART human immunodeficiency virus type 1 RNA (log10 copies/mL)</td>
<td>Median (Q1, Q3) 4.7 (4.3, 5.4)</td>
</tr>
<tr>
<td>Initial ARV regimen</td>
<td>EFV + 2/3 NRTI 16 (53%)</td>
</tr>
<tr>
<td>ARV regimen at final time point</td>
<td>ATV/r + 2 NRTI 3 (10%)</td>
</tr>
</tbody>
</table>

Abbreviations: ABC, abacavir; ART, antiretroviral therapy; ARV, antiretroviral, ATV, atazanavir; AZT, azidothymidine; EFV, efavirenz; LPV, lopinavir; NFV, Nelfinavir; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; RAL, raltegravir; 3TC, lamivudine.
Table 2. Summary of Total Human Immunodeficiency Virus Type 1 (HIV-1) DNA Levels, 2-LTR Circles, CD4+ T-cell Count, and Plasma HIV-1 RNA

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>0</th>
<th>1</th>
<th>4</th>
<th>7</th>
<th>10</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4+ T-cell count (cells/mm³)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>193 (111–360)</td>
<td>347 (257–484)</td>
<td>549 (379–768)</td>
<td>666 (520–899)</td>
<td>770 (566–924)</td>
<td>697 (472–1105)</td>
</tr>
<tr>
<td>Total HIV-1 DNA (copies/10⁶ CD4+ T-cells)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>29</td>
<td>29</td>
<td>10</td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>7319 (1920–16 469)</td>
<td>1054 (455–2193)</td>
<td>446 (185–1224)</td>
<td>434 (128–701)</td>
<td>439 (180–1030)</td>
<td>417 (105–1260)</td>
</tr>
<tr>
<td>Min-Max</td>
<td>315–144 331</td>
<td>113–9033</td>
<td>43–2664</td>
<td>49–2086</td>
<td>7–2074</td>
<td>77–1356</td>
</tr>
<tr>
<td>2-LTR circles (copies/10⁶ CD4+ T-cells)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>20/29 (69%)</td>
<td>17/30 (57%)</td>
<td>8/30 (27%)</td>
<td>6/29 (21%)</td>
<td>8/29 (28%)</td>
<td>4/10 (40%)</td>
</tr>
<tr>
<td>Median (Q1–Q3)</td>
<td>146 (48–297)</td>
<td>66 (29–89)</td>
<td>10 (3–24)</td>
<td>14 (10–23)</td>
<td>1 (1–7)</td>
<td>5 (1–11)</td>
</tr>
<tr>
<td>Min-Max</td>
<td>17–4851</td>
<td>1–155</td>
<td>2–27</td>
<td>4–25</td>
<td>0–28</td>
<td>1–15</td>
</tr>
<tr>
<td>HIV-1 RNA by single-copy HIV-1 RNA assay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Undetectable (&lt;1 copy/mL)</td>
<td>Not applicable</td>
<td>Not done</td>
<td>8 (44%)</td>
<td>10 (63%)</td>
<td>13 (76%)</td>
<td>5 (83%)</td>
</tr>
<tr>
<td>Detectable (≥1 copy/mL)</td>
<td>Not applicable</td>
<td>Not done</td>
<td>10 (56%)</td>
<td>6 (38%)</td>
<td>4 (24%)</td>
<td>1 (17%)</td>
</tr>
</tbody>
</table>

Abbreviations: HIV-1, human immunodeficiency virus type 1; LTR, long terminal repeat.

* Among 2-LTR-positive results.
CD38+/HLA-DR+ cells. At least one measure of immunological parameters was available for years 1–4 post-ART in 28 participants.

**Statistical Analysis**

Within-participant total HIV-1 DNA log_{10}copies/10^6 CD4+ T-cell slopes were estimated by fitting participant-specific linear regressions. These slopes were compared between time periods and also against the null hypothesis of no change using the Wilcoxon signed rank test. Associations with total HIV-1 DNA levels and slopes were determined using Spearman rank-based correlations (ie, with pre-ART characteristics and measures of immune recovery and immune activation) or repeated measures analyses using generalized estimating equations (ie, with HIV-1 RNA by SCA).

**RESULTS**

**Participant Characteristics**

Table 1 shows baseline characteristics of the 30 study participants. Median pre-ART age was 37 years; 77% were male; and 53% were white non-Hispanic. Median plasma HIV-1 RNA pre-ART was 4.7 log_{10}copies/mL (interquartile range [IQR], 4.3–5.4) and median CD4+ T-cell count was 193 (IQR, 111–360) cells/mm^3. The median total duration of ART with HIV-1 DNA measurements was 10.2 years.

**HIV-1 DNA Decay Kinetics**

**Total HIV-1 DNA**

All participants had detectable HIV-1 DNA at each time point. The median HIV-1 DNA level at baseline (pre-ART)
was 7319 copies/10^6 CD4+ T-cells (IQR, 1920–16 469), declining to a median of 1054 copies/10^6 CD4+ T-cells at year 1 of ART (IQR, 455–2193), then to a median of 446 copies/10^6 CD4+ T-cells after 4 years of ART (IQR, 185–1224; Table 2). Subsequent changes in the HIV-1 DNA levels were small over the next 6–8 years, reaching a median of 417 copies/10^6 CD4+ T-cells at year 12 (IQR, 105–1260; n = 10). Figures 1B and 1C illustrate the decline of total HIV-1 DNA through year 10 while on ART. The most rapid decay (7.2-fold, 86% decline) occurred within the first year, followed by a slower decline (2.2-fold) from years 1 to 4, and then a plateau during which no significant decline occurred. Specifically, HIV-1 DNA decreased from years 0–1 and 1–4 on ART, with median decay slopes of $-0.86$ (IQR, $-1.05$, $-0.59$) and $-0.11$ (IQR, $-0.17$, $-0.06$) log_{10}(copies/10^6 CD4+ T-cells)/year, respectively (comparing yearly decay years 0–1 with years 1–4; each $P < .001$ vs null of no change; Table 3). During these time intervals, 100% and 97%, respectively, had a negative HIV-1 DNA slope. HIV-1 decay slope/year was not significant from years 4 to 7 of ART (median [IQR], $-0.02$ [–0.06, 0.02]; $P = .09$) or after year 7 ($-0.006$ [–0.030, 0.015]; $P = .17$), although 69% and 66% of participants, respectively, had a negative HIV-1 DNA slope. A by-participant listing of all slopes is available as Supplementary Table 1.

Table 3. Summary of Total Human Immunodeficiency Virus Type 1 DNA Slopes Over Time

<table>
<thead>
<tr>
<th>log_{10}(Total HIV-1 DNA cps/10^6 CD4+ T-cells) Slope/Year</th>
<th>Pre-ART to Year 1 on ARTa</th>
<th>Year 1 to Year 4 on ARTb</th>
<th>Year 4 to Year 7 on ARTc</th>
<th>Year 7 Through Follow-up on ARTd,e</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>30</td>
<td>30</td>
<td>29</td>
<td>29</td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>$-0.856$ ($-1.048$, $-0.590$)</td>
<td>$-0.111$ ($-0.169$, $-0.062$)</td>
<td>$-0.017$ ($-0.061$, $0.020$)</td>
<td>$-0.006$ ($-0.030$, $0.015$)</td>
</tr>
<tr>
<td>Min, Max</td>
<td>$-1.965$, $-0.246$</td>
<td>$-0.241$, $0.057$</td>
<td>$-0.195$, $0.166$</td>
<td>$-0.415$, $0.252$</td>
</tr>
<tr>
<td>Negative slope</td>
<td>Yes</td>
<td>30 (100%)</td>
<td>29 (97%)</td>
<td>20 (69%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>9 (31%)</td>
<td>19 (66%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ART, antiretroviral therapy; HIV-1, human immunodeficiency virus type 1.
a Wilcoxon signed rank $P = <.001$, <.001, .09, and .17, respectively.
b Last year of ART follow-up with available total HIV-1 DNA: median 10 (range, 7–12; interquartile range, 10–12).

debt. Age, Pre-ART Plasma HIV-1 DNA, and RNA

Higher pre-ART HIV-1 RNA was associated with higher pre-ART HIV-1 DNA levels (Spearman = 0.71, $P < .001$) and larger declines in HIV-1 DNA from pre-ART to year 1 of ART (Spearman = $-0.42$, $P = .022$; Table 4, Figure 3A). After adjusting for pre-ART CD4+ T-cells, there was no longer evidence of an association between pre-ART HIV-1 RNA and HIV-1 DNA slope during year 1 of ART (Spearman = $-0.09$, $P = .64$). Strong, positive correlations were evident between HIV-1 DNA levels pre-ART and after 4, 7, and 10 years of ART (Spearman ≥ .75, $P < .001$; Figure 3B). Older pre-ART age was marginally associated with a smaller decline in total HIV-1 DNA from year 1 to year 4 of ART (Spearman = 0.38, $P = .039$; Table 4).

CD4+ T-cells and Immune Activation

There was a strong, negative correlation between pre-ART CD4+ T-cell count and pre-ART HIV-1 DNA (Spearman = $-0.70$, $P < .001$; Table 4, Figure 3C). In addition, higher pre-ART CD4+ T-cell count was associated with smaller decline in HIV-1 DNA from pre-ART to year 1 of ART (Spearman = 0.55, $P = .002$; Table 4, Figure 3D). A similar correlation was seen after adjusting for pre-ART HIV-1 RNA (Spearman = 0.40, $P = .033$). No association was observed between CD4+ T-cell count slopes and HIV-1 DNA slopes during either year 1 (Spearman = 0.19, $P = .32$) or years 1–4 (Spearman = 0.06, $P = .77$) of ART.

Twenty-eight of 30 participants had advanced flow data between year 1 and year 4. There was no evidence of association...
between average percent activated CD8+ cells (HLA-DR+/CD38+) during years 1–4 and HIV-1 DNA log_{10} copies/10^6 CD4+ T-cell slopes from year 1 to year 4 and from year 4 through follow-up (Spearman $P \geq .25$; Table 4), or from cross-sectional correlations at year 1 or year 4 between percent activated CD8+ cells and HIV-1 DNA levels ($r = 0.08$, $P = 0.7$, $n = 28$, and $r = 0.06$; $P = .9$, $n = 11$, respectively).

Residual Plasma Viremia (HIV-1 RNA by SCA)
At year 4 of ART, 17/18 participants with plasma HIV-1 RNA data had HIV-1 DNA data from the same specimen date. At year 4, there was no evidence of an association between HIV-1 DNA log_{10} copies/10^6 CD4+ T-cells and HIV-1 RNA when treating HIV-1 RNA values continuously (Spearman = −0.13, $P = .61$) or discretely (< vs $\geq 1$ copy/mL: Spearman = −0.073, $P = .78$). From year 4 through follow-up on ART, there was also no evidence of an association between total HIV-1 DNA log_{10} copies/10^6 CD4+ T-cells and HIV-1 RNA $\geq 1$ copy/mL ($P = .34$, repeated measures analysis). Finally, there was no evidence that total HIV-1 DNA at year 4 modified the HIV-1 RNA slope/year or the probability of HIV-1 RNA being $\geq 1$ copy/mL.

Four of the 7 participants with transient blips or ART interruption were included in these analyses. Exclusion of these participants from the analyses did not change the results; there was no evidence at year 4 of an association between HIV-1 DNA log_{10} copies/10^6 CD4+ T-cells and HIV-1 RNA when treating HIV-1 RNA values continuously (Spearman $r = 0.02$, $P = .96$) or discretely (< vs $\geq 1$ copy/mL: Spearman $r = 0.00$, $P = 1.0$).

DISCUSSION
This study reveals that total HIV-1 DNA levels in blood are remarkably stable after the fourth year of suppressive ART. Although biphasic decline of HIV-1 DNA is observed during the first 4 years of ART, little to no decay occurs thereafter. This pattern of HIV-1 DNA decay was observed consistently across the participants studied. The level of HIV-1 DNA during the plateau phase was directly correlated with the level of HIV-1 DNA before ART initiation and inversely correlated with the pretherapy CD4+ T-cell count, indicating that the number of
HIV-1–infected cells and the extent of immunodeficiency at the time of ART initiation are important determinants of the number of HIV-1 DNA-containing cells that persist after long-term ART. These findings are consistent with those reported by Hocqueloux et al [15] and von Wyl et al [16]. However, the current study extends the duration of observation and provides long-term longitudinal data on episomal HIV-1 DNA, which decays in parallel with total HIV-1 DNA during the first year of ART but stays above the limit of detection in approximately one-third of participants, raising the possibility of a longer half-life for episomal HIV-1 DNA than previously appreciated [17]. Lastly, our analyses did not reveal an association between CD8+ T-cell activation and either HIV-1 DNA levels or decay kinetics, which is contrary to recent reports [8, 18] but consistent with others [9, 19].

The largest decay of HIV-1 DNA occurred within the first year of initiating ART (86% decline). Others have reported similar findings [5, 6] that are likely due to the death of a large pool of productively infected cells and blockade of new cell infection by ART. This 7-fold decay of HIV-1 DNA contrasts with the 10,000- to 100,000-fold reduction in plasma HIV-1 RNA achieved during the first year of ART. The difference between decay of HIV-1 RNA and DNA in blood reveals that a substantial fraction of HIV-1–infected cells persist on ART but contribute little, if anything, to plasma viremia. A slower second phase of HIV-1 DNA decay occurs over the next 3 years of ART and averages a 2.2-fold decrease, likely from death of a smaller pool of infected cells with a longer half-life. Finally, a plateau phase is reached after 4 years, after which there is no significant decay for a median of 10.2 years after ART initiation.

Three mechanisms could explain the indefinite plateau phase of HIV-1 DNA. First, it could be maintained by the survival, without proliferation, of long-lived HIV–infected cells. The persistence of the same infected CD4+ T-cells over more than a decade seems unlikely given that the half-life of most immune cell subsets is short [20], although this possibility has not been excluded. Second, ongoing, complete cycles of HIV-1 replication could explain the stability of proviral HIV-1 DNA. Whether ongoing replication occurs on ART is controversial [8, 12, 18, 21, 22]. A few studies suggest that replication occurs in participants on protease inhibitors, as evidenced by an increase in 2-LTR circles after treatment intensification with the integrase inhibitor raltegravir [18, 23] or by reduction of gut-associated HIV-1 RNA [19]. However, most studies show no effect of antiretroviral intensification on persistent viremia [12, 21, 22, 24]. In addition, studies of HIV-1 population genetics on ART have not revealed consistent evidence of HIV-1 evolution [25–27]. The third potential explanation for maintenance of a plateau phase is proliferation of cells containing HIV-1 DNA [2], with expansion of some infected-cell clones and loss of other infected cells. In this case, clonal expansion would be evident by the appearance of identical proviral sequences with the same integration sites. Indeed, Wagner et al [28] have shown that the proportion of identical sequences in blood increases with time on suppressive ART despite stable HIV-1 DNA levels and that identical sequences often have the same cellular integration site; the latter provides clear evidence of clonal expansion. In addition, Maldarelli et al [29] have shown that the distance of HIV-1 populations in plasma from the most recent common ancestor decreases over time on suppressive ART, suggesting loss of HIV-1 variants. Taken together, these observations are consistent with stable HIV-1 DNA levels that result from a dynamic equilibrium between clonal expansion and loss of HIV-1 DNA–containing cells through cell death. The relative contributions of these mechanisms to stable HIV-1 DNA levels require further investigation.

Interestingly, 2-LTR circles decayed gradually but stayed detectable in 27% of participants after 7–12 years of ART. In vitro studies have estimated the half-life of HIV-1 episomes to be 10–20 hours [17, 30, 31], leading to the conclusion that they are a

### Table 4. Correlations With Human Immunodeficiency Virus Type 1 DNA Slopes

<table>
<thead>
<tr>
<th>Characteristic N</th>
<th>Pre-ART to Year 1 on ART</th>
<th>Year 1 to Year 4 on ART</th>
<th>Year 4 Through Follow-up on ART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-ART age (years) 30</td>
<td>-0.20 .29</td>
<td>0.38 .039</td>
<td>0.17 .38</td>
</tr>
<tr>
<td>Pre-ART CD4+ T-cell count (cells/mm³) 30</td>
<td>0.55 .002</td>
<td>0.15 .42</td>
<td>0.15 .43</td>
</tr>
<tr>
<td>Pre-ART HIV-1 RNA (log₁₀copies/ML) 30</td>
<td>-0.42 .22</td>
<td>-0.03 .88</td>
<td>-0.28 .13</td>
</tr>
<tr>
<td>Average activated CD8% (HLA-DR+/CD38+) during years 1–4 28</td>
<td>Not applicable</td>
<td>-0.22 .25</td>
<td>-0.11 .56</td>
</tr>
</tbody>
</table>

Abbreviations: ART, antiretroviral therapy; HIV-1, human immunodeficiency virus type 1.

a Correlation with pre-ART total HIV-1 DNA (log₁₀copies/10⁶ CD4+ T-cells): Spearman = −0.70, P < .001.
b Correlation with pre-ART total HIV-1 DNA (log₁₀copies/10⁶ CD4+ T-cells): Spearman = 0.71, P < .001.
Figure 3.  
A, Correlation between pre-antiretroviral therapy (ART) plasma human immunodeficiency virus type 1 (HIV-1) RNA \((\log_{10}\text{copies/mL})\) and total HIV-1 DNA decline pre-ART to year 1 \([\log_{10}(\text{copies/10}^6\text{CD4+ T-cells}) \text{slope/year}]\).  
B, Correlation between pre-ART total HIV-1 DNA and total HIV-1 DNA at years 4, 7, and 10 on ART.  
C, Correlation between pre-ART total HIV-1 DNA and pre-ART CD4+ T-cell count.  
D, Correlation between pre-ART CD4+ T-cell count and total HIV-1 DNA slope/year from pre-ART to year 1 on ART.
marker of recent HIV-1 replication. This may be the case for proliferating cell populations in which cell division progressively reduces the frequency of episome-containing cells. Alternatively, episomes may persist in long-lived cell populations that do not proliferate. In this regard, Pace et al. [32] showed that episomes have a half-life in vitro that exceeds 30 days. In the current study, a similar decay pattern of 2-LTR circles and total HIV-1 DNA, along with the persistence of 2-LTR circles throughout follow-up in a subset of participants, suggest that 2-LTR circles may persist in long-lived cells and are not necessarily an indicator of ongoing HIV-1 replication.

We examined the correlation between HIV-1 DNA levels and immune recovery and activation. Intriguingly, higher CD4+ T-cell levels at ART initiation were associated with lower HIV-1 DNA levels and smaller declines of total HIV-1 DNA within the first year of ART. The reason for this inverse relationship is not clear but may be a result of fewer productively infected cells in participants with higher levels of CD4+ T-cells. In addition, we did not find an association between HIV-1 decay and CD8+ T-cell activation, suggesting that immune activation is not related to the persistence of HIV-1 DNA. This finding is consistent with the recent report by Poizot-Martin et al. [9] that HIV-1 DNA levels and immune activation are not correlated after long-term ART. By contrast, Hatano et al. [8] showed a consistent relationship between immune activation and HIV-1 persistence. The latter observations were made following short-term treatment intensification, making them difficult to compare with our study. However, the immunologic assessments in our study have limitations. Our flow data are restricted to a few time points between year 1 and year 4 of ART, and we did not examine activation of CD4+ T-cells. In addition, we only quantified total HIV-1 DNA and immune activation in blood. This may not accurately reflect other sites of HIV-1 persistence, including lymphoid tissues and gut-associated lymphoid tissue [19, 33, 34]. Also, we did not observe an association between persistent plasma viremia and HIV-1 DNA levels. This is consistent with other studies that indicated that most proviruses are defective, that is, incapable of producing infectious virions [27, 35, 36]. There are several possible mechanisms by which intact HIV proviruses in CD4+ T-cells become silenced, including nuclear retention of multisliced HIV-1 RNA [37], DNA methylation [38], Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like-induced mutation [39], or histone deacetylation [40]. In addition, it is not known whether the residual virions in plasma are replication competent or defective. Finally, the cellular and compartmental sources of persistent viremia are undefined and may not be PBMCs [25]. Taken together, it is not surprising that the level of total HIV-1 DNA in PBMC is not predictive of residual viremia.

Importantly, long-term persistence of HIV-1 DNA is not an insurmountable obstacle to curing HIV-1 infection. Only a minority of proviruses (<1%) can be activated to produce infectious virus that could lead to relapse of viremia after cessation of ART [36, 41]. Consequently, curative strategies should focus on eliminating the small population of replication-competent proviruses. Furthermore, post-treatment controllers from the Viro-Immunological Sustained CONTROL After Treatment Interruption study have provided a model in which functional cure can be achieved without complete elimination of proviral DNA [42].

In conclusion, our study has revealed the remarkable stability of HIV-1 DNA during long-term suppressive ART. The mechanisms of this HIV-1 DNA stability require further elucidation. A better understanding of the dynamics of proviral persistence is needed to inform therapies to cure HIV-1 infection.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank the A5001/ALLRT team, the AIDS Clinical Trial Unit personnel, and the patients for their participation. We also thank Lorraine Pollini for her careful review of this manuscript.

Financial support. This project was funded by an award (U01AI068636) to the AIDS Clinical Trials Group from the National Institute of Allergy and Infectious Diseases (NIAID) and supported by the National Institute of Mental Health (NIMH), National Institute of Dental and Craniofacial Research (NIDCR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID or the National Institutes of Health. This work was also supported by grants from the AIDS Clinical Trials Group to the Pittsburgh Virology Specialty Laboratory (AI068636), the Statistical and Data Management Center (UM1 AI068634; AA18885), and the Clinical Trials Unit at the University of Pittsburgh (AI069494).

Potential conflicts of interest. J. W. M. is a consultant to Gilead Sciences and holds share options in RFS Pharmaceuticals. No other conflicts are reported. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References